Esteban Braggio
Mayo Clinic · 535 works · 10,686 citations · h-index 50
Top works
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
- Clonal competition with alternating dominance in multiple myeloma
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
- Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
- Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas
- BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
- Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
- Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma
- Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenstrom's Macroglobulinemia
- Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
- Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
- Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
- Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
- SnapShot: Multiple Myeloma
- Diagnosis and Management of Waldenström Macroglobulinemia
- Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing
- Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6
- Precancer Atlas to Drive Precision Prevention Trials